These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35606821)

  • 21. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness.
    Chen J; Qiu S; Li W; Wang K; Zhang Y; Yang H; Liu B; Li G; Li L; Chen M; Lan J; Niu J; He P; Cheng L; Fan G; Liu X; Song X; Xu C; Wu H; Wang H
    Cell Res; 2023 May; 33(5):341-354. PubMed ID: 36882513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing.
    Zhang M; Jin X; Sun R; Xiong X; Wang J; Xie D; Zhao M
    J Transl Med; 2021 Dec; 19(1):499. PubMed ID: 34876185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
    Sun W; Jiang Z; Jiang W; Yang R
    Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
    Wachsmann TLA; Wouters AK; Remst DFG; Hagedoorn RS; Meeuwsen MH; van Diest E; Leusen J; Kuball J; Falkenburg JHF; Heemskerk MHM
    Oncoimmunology; 2022; 11(1):2033528. PubMed ID: 35127255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
    Holzinger A; Abken H
    Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of response and resistance to CAR T cell therapy.
    Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
    Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
    Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
    Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Who wins the combat, CAR or TCR?
    Yun K; Siegler EL; Kenderian SS
    Leukemia; 2023 Oct; 37(10):1953-1962. PubMed ID: 37626090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
    Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
    J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T cells in solid tumors: challenges and opportunities.
    Marofi F; Motavalli R; Safonov VA; Thangavelu L; Yumashev AV; Alexander M; Shomali N; Chartrand MS; Pathak Y; Jarahian M; Izadi S; Hassanzadeh A; Shirafkan N; Tahmasebi S; Khiavi FM
    Stem Cell Res Ther; 2021 Jan; 12(1):81. PubMed ID: 33494834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations.
    Wang L
    Curr Res Transl Med; 2022 Jan; 70(1):103320. PubMed ID: 34768218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.